+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting a large observational study involving 5,000 adult patients across about 50 regions in Russia who have uncontrolled severe asthma and are receiving standard treatments except biologic therapies. The study aims to better understand the characteristics, treatment patterns, and clinical outcomes of these patients, as there is currently limited data on this population in Russia. The study will not interfere with routine clinical care and is designed to collect comprehensive real-world information. Participants will have one study visit to gather demographic and clinical data without any additional diagnostic or therapeutic procedures beyond their usual care. This cross-sectional study will take place at 50 outpatient centers experienced in treating uncontrolled severe asthma, enrolling about 100 patients per region. The study will run from June 2024 to June 2027. During the single visit, researchers will collect information such as patients treatment regimens, use of oral corticosteroids, demographic details, clinical characteristics including comorbidities, lung function, and biomarkers like blood eosinophil counts and Immunoglobulin E levels. They will analyze these data to characterize treatment patterns and clinical outcomes in this population. No interventions are given, and patient safety is monitored through standard medical practice.

Age: 18Years +All Genders
40 locations
T

Actively Recruiting

Researchers are investigating the combined use of best endovascular treatment and gene therapy for people with severe lower limb ischemia, specifically those classified under Rutherford categories 4 and 5 and Fontaine grades III and IV. This trial aims to compare this combination approach to standard endovascular treatment alone, hypothesizing that adding gene therapy may reduce repeat interventions and high amputations, and increase the time between needed treatments. The study addresses a critical medical need as current treatments often require multiple interventions and have high rates of major amputations, which lead to disability and increased mortality. The study has two groups one receiving the standard best endovascular treatment, which includes arterial stenting or balloon angioplasty, and the other group receiving this same treatment plus gene therapy with Neovasculgen. Neovasculgen is a drug containing a supercoiled plasmid DNA that stimulates new blood vessel growth. This gene therapy is given by intramuscular injection in two doses, on days 7 and 21 after the endovascular procedure. The trial is randomized and controlled, with patients assigned to either treatment group. Participants will be monitored over two years to assess outcomes such as freedom from repeated interventions and high amputations, pain levels, ulcer healing, walking distance, and overall survival. The study includes regular clinical and instrumental assessments, including hemodynamic measurements and safety monitoring for serious adverse events. The research team will also track major adverse limb and cardiovascular events during this period. Participants will need to attend follow-up visits and comply with study instructions throughout the study duration.

Age: 18Years +All GendersPhase 4
1 location